In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

U.S. stock futures are signaling a slightly positive start for Friday’s session, suggesting equities may attempt a rebound ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst performance since 2008. Is the company in big trouble, or could this actually be a ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...